Dermata Therapeutics (DRMA) Long-Term Deferred Tax (2021 - 2024)
Dermata Therapeutics (DRMA) posted quarterly Long-Term Deferred Tax of $3.0 million for Q4 2023, up 82.93% quarter-over-quarter from $1.6 million in Q4 2021.
Dermata Therapeutics (DRMA) Long-Term Deferred Tax (2021 - 2024) Analysis & Trends
Dermata Therapeutics' Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $3.0 million for Q4 2023.
- In Q4 2023, Long-Term Deferred Tax changed N/A year-over-year to $3.0 million; the TTM figure through Dec 2023 stood at $3.0 million (changed N/A YoY), while the FY2023 annual figure was $3.0 million, changed N/A from the prior year.
- Long-Term Deferred Tax for Q4 2023 stood at $3.0 million, up from $1.6 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $3.0 million in Q4 2023, with the low at $1.6 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Dermata Therapeutics | 5.33 Mn | 5.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 8.02 Mn |
| Dec 31, 2023 | 2.98 Mn |
| Dec 31, 2021 | 1.63 Mn |